Journal for ImmunoTherapy of Cancer

Journal

Publication Venue For

  • Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.  10. 2022
  • Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.  10. 2022
  • Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: Interim results from GARNET - A phase I, single-arm study.  10. 2022
  • Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study.  10. 2022
  • G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes.  10. 2022
  • First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer.  9. 2021
  • Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis.  9. 2021
  • Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.  9. 2021
  • Obesity diminishes response to PD-1-based immunotherapies in renal cancer.  8. 2020
  • Impact of body composition on outcomes from anti-PD1 +/-anti-CTLA-4 treatment in melanoma.  8. 2020
  • Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service..  8. 2020
  • Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.  8. 2020
  • Corrections to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma (Journal for ImmunoTherapy of Cancer (2019) 7 (139) DOI: 10.1186/s40425-019-0621-1).  7. 2019
  • Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.  7. 2019
  • Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy..  7:10. 2019
  • Smoldering myocarditis following immune checkpoint blockade.  5. 2017
  • Electronic International Standard Serial Number (eissn)

  • 2051-1426